ArticleWorld journal of surgical oncology2026
Development and validation of a phospholipid metabolism-associated lncRNA model for prognostic stratification and therapeutic guidance in HNSCC.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Alterations in phospholipid metabolism are increasingly recognized as critical in cancer progression, yet their specific contributions to head and neck squamous cell carcinoma (HNSCC) remain unclear. This study aimed to establish a prognostic model based on phospholipid metabolism-related long non-coding RNAs (lncRNAs) to predict clinical outcomes in HNSCC patients. Transcriptomic data from The Cancer Genome Atlas (TCGA) were analyzed to identify differentially expressed lncRNAs linked to phospholipid metabolism. Using univariate and multivariate Cox regression analyses, a 10-lncRNA signature (AC104041.1, AC106820.3, AL355488.1, LINC01305, AC133644.1, AC091185.1, AL158166.1, AL512274.1, DBH-AS1, AC025176.1) was developed. The model’s predictive accuracy was confirmed through Kaplan–Meier survival analysis, time-dependent receiver operating characteristic (ROC) curves, and decision curve analysis (DCA), surpassing traditional clinical indicators for overall survival (OS). Gene set enrichment analysis, immune profiling, and drug sensitivity testing revealed distinct biological differences between clusters. Low-risk patients and those in cluster 2 exhibited better prognoses, enhanced immune infiltration, and heightened immune activity, while high-risk patients in cluster 1 showed increased sensitivity to chemotherapeutic agents. Functional assays demonstrated that AL158166.1 knockdown inhibited HNSCC cell proliferation, migration, invasion, and phospholipid metabolism, likely through suppression of the PI3K/AKT/mTOR pathway. These findings suggest that AL158166.1 plays a pivotal role in HNSCC progression. In conclusion, the proposed lncRNA-based prognostic model provides a reliable tool for survival prediction and personalized treatment guidance in HNSCC, highlighting promising therapeutic targets and advancing precision immunotherapy and chemotherapy strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.